Key Takeaways

President Trump has since been taken to the Walter Reed National Military Medical Center in Bethesda, Maryland, “out of an abundance of caution, and at the recommendation of his physician and medical experts,” according to press secretary Kayleigh McEnany.

Here’s what we know about Regeneron’s antibody cocktail.

President Trump Tests Positive For COVID-19: 6 Things We Know

What Is An Antibody Cocktail?

Regeneron generates these antibodies outside of the body, derived from either genetically-humanized mice or convalescent (recovered) humans. These antibodies can be delivered via injection, providing passive immunity—short-term immunity resulting from the introduction of antibodies from another person or animal—though they must be re-administered to remain effective over time. These antibodies can also potentially treat an existing infection.

Findings Are Preliminary

On Tuesday, Regeneron announced promising results for its antibody cocktail, called REGN-COV2. In preliminary results from a trial of 275 non-hospitalized COVID-19 patients, the drug reduced viral load and the time to alleviate symptoms in non-hospitalized patients with COVID-19. But the study has yet to be peer-reviewed, and the drug has not received approval from the U.S. Food and Drug Administration (FDA).

Initial data from the study found that this treatment showed the greatest improvements in patients “who had not mounted their own effective immune response prior to treatment,” according to the Regeneron press release.

A high dose (8 grams), which is the amount given to President Trump, seemed to have the greatest effect. But in the group with detectable levels of their own antibodies, even a lower dose (2.4 grams) of the Regeneron antibodies seemed to result in patients getting better faster.

For patients who did not have detectable antibodies at the study’s outset, Regeneron’s antibody cocktail improved symptoms as well. In this group, symptoms were alleviated in 13 days on placebo, eight days in the high-dose group, and six days in the low-dose group.

What This Means For YouRegeneron’s antibody cocktail is still in clinical trials and not yet available to the public. But results from their initial trials are promising, and the cocktail may be available as a treatment for COVID-19 patients in the near future.

What This Means For You

Regeneron’s antibody cocktail is still in clinical trials and not yet available to the public. But results from their initial trials are promising, and the cocktail may be available as a treatment for COVID-19 patients in the near future.

Who Can Get It?

Certain criteria are require for this usage:

Regeneron plans to rapidly discuss initial clinical trial results with regulatory authorities.

The information in this article is current as of the date listed, which means newer information may be available when you read this. For the most recent updates on COVID-19, visit ourcoronavirus news page.

3 SourcesVerywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Cision. PR Newswire.Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19. June 11, 2020.Regeneron.Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-hospitalized COVID-19 Patients. September 29, 2020.Mayo Clinic.I’ve Heard That Compassionate Use is a Way to Get Access to Experimental Treatments. How Does it Work?February 12, 2020.

3 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.Cision. PR Newswire.Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19. June 11, 2020.Regeneron.Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-hospitalized COVID-19 Patients. September 29, 2020.Mayo Clinic.I’ve Heard That Compassionate Use is a Way to Get Access to Experimental Treatments. How Does it Work?February 12, 2020.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read oureditorial processto learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.

Cision. PR Newswire.Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19. June 11, 2020.Regeneron.Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-hospitalized COVID-19 Patients. September 29, 2020.Mayo Clinic.I’ve Heard That Compassionate Use is a Way to Get Access to Experimental Treatments. How Does it Work?February 12, 2020.

Cision. PR Newswire.Regeneron Begins First Clinical Trials of Anti-Viral Antibody Cocktail REGN-COV2 for the Treatment and Prevention of COVID-19. June 11, 2020.

Regeneron.Regeneron’s REGN-COV2 Antibody Cocktail Reduced Viral Levels and Improved Symptoms in Non-hospitalized COVID-19 Patients. September 29, 2020.

Mayo Clinic.I’ve Heard That Compassionate Use is a Way to Get Access to Experimental Treatments. How Does it Work?February 12, 2020.

Meet Our Medical Expert Board

Share Feedback

Was this page helpful?Thanks for your feedback!What is your feedback?OtherHelpfulReport an ErrorSubmit

Was this page helpful?

Thanks for your feedback!

What is your feedback?OtherHelpfulReport an ErrorSubmit

What is your feedback?